aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate Efzofitimod In Patients With Chronic, Symptomatic Pulmonary Sarcoidosis With Restrictive Lung Disease; Expects To Initiate Study-Related Activities In Q4 2026

aTyr Pharma has received FDA alignment on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, targeting patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The global trial will enroll approximately 372 patients and is set to begin study-related activities in Q4 2026, focusing on efficacy and safety over a 54-week period. The study's primary endpoint will assess changes in forced vital capacity (FVC) at week 48, supported by previous positive data from a subgroup analysis. The company will seek additional capital for the study through various funding methods.